Seoul Pharma KRX:018680KOSDAQ
서울제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, Seoul Pharma reported revenue of ₩11.8bn, down 2.1% year on year, and an operating loss of ₩343m. Seoul Pharma (서울제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Seoul Pharma quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩11.8bn | -2.1% | −₩343m margin −2.9% | −₩318m |
| Q1 2026 | ₩12.1bn | -6.4% | −₩186m margin −1.5% | −₩192m |
| Q4 2025 derived | ₩13.6bn | -2.0% | −₩217m margin −1.6% | −₩376m |
| Q3 2025 | ₩13.6bn | +1.8% | −₩34m margin −0.2% | ₩2.6bn |
| Q2 2025 | ₩12.0bn | -6.5% | −₩914m margin −7.6% | −₩1.3bn |
| Q1 2025 | ₩12.9bn | -4.0% | −₩115m margin −0.9% | −₩164m |
| Q4 2024 derived | ₩13.9bn | +5.4% | ₩629m margin 4.5% | ₩661m |
| Q3 2024 | ₩13.4bn | -1.4% | ₩70m margin 0.5% | ₩173m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Seoul Pharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.